SOPHiA GENETICS (SOPH) Q3 2026 earnings summary

Executive summary

• Q3 revenue was $24.267M, up 25% YoY; record analysis volume, U.S. growth and BioPharma momentum supported performance.

• Platform analyses reached a record 118,000, up 19% YoY; adjusted EBITDA loss narrowed 31% to $6.071M.

• FY26 revenue is expected at the upper end of $94M–$96M guidance; positive adjusted EBITDA is targeted in H2 2027.

Financial highlights

• Q3 revenue was $24.267M vs. $19.462M a year earlier, up 25% reported and 26% at constant currency; 9M revenue was $69.265M, up 25% reported.

• IFRS gross profit was $15.934M and gross margin 65.7%; adjusted gross profit was $17.646M and adjusted gross margin 72.8%.

• Operating loss was $17.824M vs. $17.862M YoY; net loss was $20.272M vs. $20.021M.

• Adjusted EBITDA loss was $6.071M vs. $8.838M in Q3 2025; 9M adjusted EBITDA loss was $24.108M vs. $30.338M.

Outlook and guidance

• FY26 revenue is expected at the upper end of the previously issued $94M–$96M range; FX may partly offset strong underlying performance.

• FY26 adjusted EBITDA loss guidance was reaffirmed at $29M–$32M, compared with $41.5M in FY25.

• Positive adjusted EBITDA is targeted in H2 2027; further improvement is expected in Q4 2026.

• Management said 95% of 2027 growth is covered by signed business; revenue conversion depends on customer validation and implementation timing.